NCT05491421 is a Phase 1 clinical trial of ZT002 in Type 2 Diabetes Mellitus, sponsored by QL Biopharmaceutical Australia Pty Ltd.

Who is sponsoring NCT05491421?

NCT05491421 is sponsored by QL Biopharmaceutical Australia Pty Ltd.

What drugs are being tested in NCT05491421?

Interventions in NCT05491421: ZT002, Placebo.

What condition does NCT05491421 study?

NCT05491421 studies Type 2 Diabetes Mellitus.

Is NCT05491421 still recruiting?

NCT05491421 is currently completed. Last updated 16 January 2026.

Last reviewed 2026-01-16 · How we verify

NCT05491421

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Study of ZT002 in Healthy Participants

Completed Phase 1 Last updated 16 January 2026

What this trial tests

Phase 1 trial testing ZT002 in Type 2 Diabetes Mellitus in 32 participants. Completed in 28 April 2023.

Timeline

2 September 2022

Primary endpoint
28 April 2023

28 April 2023

Quick facts

Lead sponsor	QL Biopharmaceutical Australia Pty Ltd
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	treatment
Enrollment	32
Start date	2 September 2022
Primary completion	28 April 2023
Estimated completion	28 April 2023
Sites	1 location across Australia

Drugs / interventions tested

ZT002
Placebo

Conditions studied

Type 2 Diabetes Mellitus — all drugs for Type 2 Diabetes Mellitus →

Sponsor

QL Biopharmaceutical Australia Pty Ltd

Who can join

Adults 18 to 55, any sex, with Type 2 Diabetes Mellitus. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study will comprise a randomized, parallel assignment, double blind, placebo controlled, single and multiple ascending dose, safety, tolerability and pharmacokinetic study of ZT002 in healthy participants.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of ZT002

Trials testing the same drug.

NCT06423872 — A SAD Study of ZT002 Injection in Healthy Participants · Phase 1 · completed

Other recruiting trials for Type 2 Diabetes Mellitus

Currently open trials in the same condition.

NCT07351058 — A Clinical Study to Evaluate the Effects of RO7795068 in Participants With Obesity or Overweight and Type 2 Diabetes · Phase 3 · recruiting
NCT07373938 — Carotid Wall Texture as a Cardiovascular Risk Biomarker in Type 2 Diabetes Mellitus · recruiting
NCT07433062 — A Study to Evaluate the Effect of AZD6793 on the Pharmacokinetics and Pharmacodynamics of Metformin in Participants With · Phase 1 · recruiting
NCT07276776 — An Evaluation of the Omnipod® M System in Adults With Type 2 Diabetes · NA · active not recruiting
NCT07232537 — An Observational Study Called FINE-REAL Korea to Learn More About the Use of the Drug Finerenone in People With Chronic · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05491421 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by QL Biopharmaceutical Australia Pty Ltd
Last refreshed: 16 January 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05491421.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing